Skip to Main content
Number of documents

118

Dr. Max CHAFFANET


Journal articles117 documents

  • Renaud Sabatier, Cécile Vicier, Séverine Garnier, Arnaud Guille, Nadine Carbuccia, et al.. Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study. Molecular Oncology, Elsevier, 2022, ⟨10.1002/1878-0261.13188⟩. ⟨hal-03583253⟩
  • Chaïma Cherif, Dang Tan Nguyen, Clément Paris, Thi Khanh Le, Thibaud Sefiane, et al.. Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity. Oncogene, Nature Publishing Group, 2022, 41 (1), pp.125-137. ⟨10.1038/s41388-021-02039-2⟩. ⟨hal-03599176⟩
  • Renaud Sabatier, Cécile Vicier, Séverine Garnier, Arnaud Guille, Nadine Carbuccia, et al.. Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study. Molecular Oncology, Elsevier, In press, ⟨10.1002/1878-0261.13188⟩. ⟨hal-03606435⟩
  • Cecile Vicier, Patrick Sfumato, Nicolas Isambert, Florence Dalenc, Marie Robert, et al.. TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients. European Journal of Cancer, Elsevier, 2021, 159, pp.205 - 214. ⟨10.1016/j.ejca.2021.09.040⟩. ⟨inserm-03647613⟩
  • Jean-Luc Raoul, Sandrine Oziel-Taieb, Thierry Lecomte, José Adelaide, Arnaud Guille, et al.. Case report: Two cases of metastatic pancreatoblastoma in adults: efficacy of Folfirinox and implication of the wnt/β-catenin pathway in genomic analysis. Frontiers in Oncology, Frontiers, 2021, 11, pp.1-8. ⟨10.3389/fonc.2021.564506⟩. ⟨hal-03623119⟩
  • François Bertucci, Anthony Gonçalves, Arnaud Guille, José Adelaïde, Séverine Garnier, et al.. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. Genome Medicine, BioMed Central, 2021, 13 (1), pp.87. ⟨10.1186/s13073-021-00897-9⟩. ⟨hal-03583277⟩
  • Cecile Vicier, Patrick Sfumato, Nicolas Isambert, Florence Dalenc, Marie Robert, et al.. TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients. European Journal of Cancer, Elsevier, 2021, 159, pp.205-214. ⟨10.1016/j.ejca.2021.09.040⟩. ⟨hal-03622797⟩
  • Renaud Sabatier, Cécile Vicier, Séverine Garnier, Arnaud Guille, Nadine Carbuccia, et al.. 739P Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial. Annals of Oncology, Elsevier, 2021, 32 (15_suppl), pp.S737-S738. ⟨10.1016/j.annonc.2021.08.1181⟩. ⟨hal-03622737⟩
  • A. Takedachi, E. Despras, S. Scaglione, R. Guérois, J. Guervilly, et al.. SLX4 interacts with RTEL1 to prevent transcription-mediated DNA replication perturbations. Nature Structural and Molecular Biology, Nature Publishing Group, 2020, 27 (5), pp.438-449. ⟨10.1038/s41594-020-0419-3⟩. ⟨hal-02995970⟩
  • François Bertucci, Charlotte Rypens, Pascal Finetti, Arnaud Guille, José Adélaïde, et al.. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non‐inflammatory breast cancers. Molecular Oncology, Elsevier, 2020, 14 (3), pp.504-519. ⟨10.1002/1878-0261.12621⟩. ⟨hal-03623678⟩
  • A. Collignon, M. A Hospital, C. Montersino, F. Courtier, A. Charbonnier, et al.. A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study. Blood Cancer Journal, Nature Publishing Group, 2020, 10 (6), pp.64. ⟨10.1038/s41408-020-0330-5⟩. ⟨inserm-03038330⟩
  • A. Takedachi, E. Despras, S. Scaglione, R. Guérois, J. Guervilly, et al.. Publisher Correction: SLX4 interacts with RTEL1 to prevent transcription-mediated DNA replication perturbations. Nature Structural and Molecular Biology, Nature Publishing Group, 2020, 27 (6), pp.604-604. ⟨10.1038/s41594-020-0447-z⟩. ⟨hal-02997075⟩
  • A. Takedachi, E. Despras, S. Scaglione, R. Guérois, J. Guervilly, et al.. SLX4 interacts with RTEL1 to prevent transcription-mediated DNA replication perturbations. Nature Structural and Molecular Biology, Nature Publishing Group, 2020, 27 (5), pp.438-449. ⟨10.1038/s41594-020-0419-3⟩. ⟨hal-03079782⟩
  • A Takedachi, E Despras, S Scaglione, R Guérois, J Guervilly, et al.. SLX4 interacts with RTEL1 to prevent transcription-mediated DNA replication perturbations.. Nature Structural and Molecular Biology, Nature Publishing Group, 2020, 27 (5), pp.438-449. ⟨10.1038/s41594-020-0419-3⟩. ⟨hal-03023347⟩
  • Shuichi Aoki, Koetsu Inoue, Sebastian Klein, Stefan Halvorsen, Jiang Chen, et al.. Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors. Cancers, MDPI, 2019, 11 (4), pp.497. ⟨10.3390/cancers11040497⟩. ⟨hal-03583447⟩
  • Frédéric Courtier, Séverine Garnier, Nadine Carbuccia, Arnaud Guille, José Adélaide, et al.. Targeted molecular characterization shows differences between primary and secondary myelofibrosis. Genes, Chromosomes and Cancer, Wiley, 2019, 59 (1), pp.30-39. ⟨10.1002/gcc.22789⟩. ⟨hal-03634203⟩
  • Luc Xerri, José Adelaïde, Morgan Avenin, Arnaud Guille, Sébastien Taix, et al.. Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution. Histopathology, Wiley, 2019, 74 (4), pp.654-662. ⟨10.1111/his.13783⟩. ⟨hal-02533424⟩
  • Francois Bertucci, Charlotte Ng, Anne Patsouris, Nathalie Droin, Salvatore Piscuoglio, et al.. Author Correction: Genomic characterization of metastatic breast cancers. Nature, Nature Publishing Group, 2019, 572 (7767), pp.E7-E7. ⟨10.1038/s41586-019-1380-3⟩. ⟨hal-02504834⟩
  • Renaud Sabatier, Marc Lopez, Arnaud Guille, Emilien Billon, Nadine Carbuccia, et al.. High Response to Cetuximab in a Patient With EGFR -Amplified Heavily Pretreated Metastatic Triple-Negative Breast Cancer. JCO precision oncology, American Society of Clinical Oncology, 2019, pp.1-8. ⟨10.1200/po.18.00310⟩. ⟨hal-03623686⟩
  • Lorène Seguin, Max Chaffanet, Séverine Garnier, José Adélaïde, Nadine Carbuccia, et al.. Major Response to Carboplatin in a Patient With Metastatic Triple-Negative Breast Cancer With Somatic Mutation of BRCA1 and Loss of RAD51B. JCO precision oncology, American Society of Clinical Oncology, 2019, pp.1-9. ⟨10.1200/po.18.00362⟩. ⟨hal-03623688⟩
  • Marguerite Tyran, Nadine Carbuccia, Séverine Garnier, Arnaud Guille, José Adelaïde, et al.. A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases. Cancers, MDPI, 2019, 11 (5), pp.665. ⟨10.3390/cancers11050665⟩. ⟨hal-02533361⟩
  • Francois Bertucci, Charlotte Ng, Anne Patsouris, Nathalie Droin, Salvatore Piscuoglio, et al.. Genomic characterization of metastatic breast cancers. Nature, Nature Publishing Group, 2019, 569 (7757), pp.560-564. ⟨10.1038/s41586-019-1056-z⟩. ⟨hal-02504838⟩
  • Maroua Manai, Pascal Finetti, Nesrine Mejri, Salma Athimni, Daniel Birnbaum, et al.. Inflammatory breast cancer in 210�patients: A retrospective study on epidemiological, anatomo‑clinical features and therapeutic results. Molecular and Clinical Oncology, Spandidos Publications, 2018, 10 (2), pp.223-230. ⟨10.3892/mco.2018.1773⟩. ⟨hal-02530356⟩
  • L. Seguin, M. Chaffanet, R. Sabatier, A. Jose, S. Garnier, et al.. A major response to carboplatin in a metastatic triple-negative breast cancer patient with somatic mutation of BRCA1 and RAD51B: When chemotherapy meets precision medicine. Annals of Oncology, Elsevier, 2018, 29 (6), ⟨10.1093/annonc/mdy314.030⟩. ⟨hal-02143656⟩
  • Raoudha Doghri, Maroua Manai, Pascal Finetti, Maha Driss, Emilie Agavnian, et al.. Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value. International Journal of Molecular Sciences, MDPI, 2018, 19 (1), ⟨10.3390/ijms19010041⟩. ⟨hal-02143620⟩
  • Brice Chanez, Max Chaffanet, José Adélaide, Jeanne Thomassin, Séverine Garnier, et al.. Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer. JCO precision oncology, American Society of Clinical Oncology, 2018, pp.1-8. ⟨10.1200/po.18.00083⟩. ⟨hal-03623699⟩
  • Luc Xerri, José Adelaïde, Cornel Popovici, Séverine Garnier, Arnaud Guille, et al.. CDKN2A/B Deletion and Double-hit Mutations of the MAPK Pathway Underlie the Aggressive Behavior of Langerhans Cell Tumors. American Journal of Surgical Pathology, Lippincott, Williams & Wilkins, 2018, 42 (2), pp.150 - 159. ⟨10.1097/PAS.0000000000000989⟩. ⟨hal-01788565⟩
  • Norbert Vey, Marie Anne Hospital, Aude Collignon, yves Collette, Daniel Birnbaum, et al.. Cegal Protocol : Evaluation of the Feasibility of a Chemogenomic Approach to Identify Personalized Therapy for Relapse or Refractory AML Patients. Blood, American Society of Hematology, 2018, 132 (1), ⟨10.1182/blood-2018-99-119263⟩. ⟨hal-02143630⟩
  • Emmanuelle Charafe-Jauffret, Julien Wicinski, Olivier Cabaud, Marc Lopez, Stephane Audebert, et al.. Ex vivo CSC assays for personalized testing of drug susceptibility in advanced breast cancer. CANCER RESEARCH, 2018, 78 (4, S). ⟨hal-02143678⟩
  • N Cervera, N Carbuccia, M Mozziconacci, A Adélaïde, S Garnier, et al.. Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification. Blood Cancer Journal, Nature Publishing Group, 2017, 7 (8), pp.e594. ⟨10.1038/bcj.2017.68⟩. ⟨hal-01789525⟩
  • Maroua Manai, Jeanne Thomassin-Piana, Amor Gamoudi, Pascal Finetti, Marc Lopez, et al.. MARCKS protein overexpression in inflammatory breast cancer. Oncotarget, Impact journals, 2017, 8, pp.6246 - 6257. ⟨10.18632/oncotarget.14057⟩. ⟨hal-01787705⟩
  • François Bertucci, Max Chaffanet, Daniel Birnbaum. An ICGC major achievement in breast cancer: a comprehensive catalog of mutations and mutational signatures. Chinese Clinical Oncology, AME Publishing Company, 2017, 6 (1), pp.4 - 4. ⟨10.21037/cco.2016.11.01⟩. ⟨hal-01787356⟩
  • Frédéric Courtier, Nadine Carbuccia, Séverine Garnier, Arnaud Guille, José Adelaïde, et al.. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases. Haematologica, Ferrata Storti Foundation, 2016, 102 (1), pp.e11-e14. ⟨10.3324/haematol.2016.152363⟩. ⟨hal-01789589⟩
  • N Cervera, N Carbuccia, S Garnier, A Guille, J Adélaïde, et al.. Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing. Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2016, 30 (4), pp.966-970. ⟨10.1038/leu.2015.198⟩. ⟨hal-03634236⟩
  • José Adélaide, Nathalie Cervera, Nadine Carbuccia, Séverine Garnier, Arnaud Guille, et al.. Epigenetically centered evolution in an example of myeloid malignancy. American Journal of Hematology, Wiley, 2016, 91 (9), pp.E361-E362. ⟨10.1002/ajh.24450⟩. ⟨hal-03634232⟩
  • François Bertucci, Pascal Finetti, Arnaud Guille, José Adélaïde, Séverine Garnier, et al.. Comparative genomic analysis of primary tumors and metastases in breast cancer. Oncotarget, Impact journals, 2016, 7 (19), pp.27208-27219. ⟨10.18632/oncotarget.8349⟩. ⟨hal-03623731⟩
  • Tania M. Puvirajesinghe, François Bertucci, Ashish Jain, Pierluigi Scerbo, Edwige Belotti, et al.. Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2–JNK signalling in breast cancer. Nature Communications, Nature Publishing Group, 2016, 7, pp.10318. ⟨10.1038/ncomms10318⟩. ⟨hal-01447570⟩
  • Anthony Gonçalves, François Bertucci, Arnaud Guille, Severine Garnier, José Adelaide, et al.. Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. Oncotarget, Impact journals, 2016, 7 (48), pp.79428-79441. ⟨10.18632/oncotarget.12714⟩. ⟨hal-03623724⟩
  • David Birnbaum, François Bertucci, Pascal Finetti, José Adélaïde, Marc Giovannini, et al.. Expression of Genes with Copy Number Alterations and Survival of Patients with Pancreatic Adenocarcinoma.. Cancer Genomics and Proteomics, International Institute of Anticancer Research, 2016, 13 (3), pp.191-200. ⟨hal-03583479⟩
  • Khalid Oumzil, Sébastien Benizri, Giovanni Tonelli, Cathy Staedel, Ananda Appavoo, et al.. pH-Cleavable Nucleoside Lipids: A New Paradigm for Controlling the Stability of Lipid-Based Delivery Systems. ChemMedChem, Wiley-VCH Verlag, 2015, 10, pp. 1797-1801. ⟨10.1002/cmdc.201500381⟩. ⟨hal-01543569⟩
  • y Collette, Thomas Prébet, A. Goubard, José Adelaïde, R Castellano, et al.. Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia. Blood Cancer Journal, Nature Publishing Group, 2015, 5 (e292), ⟨10.1038/bcj.2015.13⟩. ⟨hal-01218497⟩
  • Renaud Sabatier, Pascal Finetti, Emilie Mamessier, José Adelaide, Max Chaffanet, et al.. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget, Impact journals, 2015, 6 (7), pp.5449-5464. ⟨10.18632/oncotarget.3216⟩. ⟨hal-03583484⟩
  • Rita El Helou, Julien Wicinski, Arnaud Guille, José Adelaïde, Pascal Finetti, et al.. Brief Reports: A Distinct DNA Methylation Signature Defines Breast Cancer Stem Cells and Predicts Cancer Outcome. STEM CELLS, AlphaMed Press, 2014, 32 (11), pp.3031-3036. ⟨10.1002/stem.1792⟩. ⟨hal-01431934⟩
  • Stéphanie Cornen, Arnaud Guille, José Adelaïde, Lynda Addou-Klouche, Pascal Finetti, et al.. Candidate Luminal B Breast Cancer Genes Identified by Genome, Gene Expression and DNA Methylation Profiling. PLoS ONE, Public Library of Science, 2014, 9 (1), pp.e81843. ⟨10.1371/journal.pone.0081843⟩. ⟨hal-01614950⟩
  • M. Brecqueville, J. Rey, R. Devillier, A. Guille, R. Gillet, et al.. Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase. Haematologica, Ferrata Storti Foundation, 2014, 99 (1), pp.37-45. ⟨10.3324/haematol.2013.091454⟩. ⟨hal-03634242⟩
  • Pascal Finetti, Arnaud Guille, José Adelaide, Daniel Birnbaum, Max Chaffanet, et al.. ESPL1 is a candidate oncogene of luminal B breast cancers. Breast Cancer Research and Treatment, Springer Verlag, 2014, 147 (1), pp.51-59. ⟨10.1007/s10549-014-3070-z⟩. ⟨hal-03623756⟩
  • Mandy Brecqueville, José Adélaïde, François Bertucci, Pascal Finetti, Max Chaffanet, et al.. Alterations of polycomb gene BMI1 in human myeloproliferative neoplasms. Cell Cycle, Taylor & Francis, 2014, 11 (16), pp.3141-3142. ⟨10.4161/cc.21114⟩. ⟨hal-03623775⟩
  • Emilie Mamessier, J. Song, C. Eberle, S. Pack, C. Drevet, et al.. Early lesions of follicular lymphoma: a genetic perspective. Haematologica, Ferrata Storti Foundation, 2014, 99 (3), pp.481 - 488. ⟨10.3324/haematol.2013.094474⟩. ⟨hal-01765646⟩
  • Renaud Sabatier, Pascal Finetti, Arnaud Guille, José Adelaïde, Max Chaffanet, et al.. Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization. Molecular Cancer, BioMed Central, 2014, 13, pp.228. ⟨10.2174/156652412798376134⟩. ⟨inserm-01192813⟩
  • François Bertucci, Corinne Bouvier‐labit, Pascal Finetti, José Adélaïde, Philippe Metellus, et al.. Comprehensive genome characterization of solitary fibrous tumors using high‐resolution array‐based comparative genomic hybridization. Genes, Chromosomes and Cancer, Wiley, 2013, 52 (2), pp.156-164. ⟨10.1002/gcc.22015⟩. ⟨hal-03623772⟩
  • Emmanuelle Charafe-Jauffret, Christophe Ginestier, François Bertucci, Olivier Cabaud, Julien Wicinski, et al.. ALDH1-Positive Cancer Stem Cells Predict Engraftment of Primary Breast Tumors and Are Governed by a Common Stem Cell Program. Cancer Research, American Association for Cancer Research, 2013, 73 (24), pp.7290-7300. ⟨10.1158/0008-5472.CAN-12-4704⟩. ⟨hal-01431937⟩
  • Arnaud Guille, Max Chaffanet, Daniel Birnbaum. Signaling pathway switch in breast cancer.. Cancer Cell International, BioMed Central, 2013, 13 (1), pp.66. ⟨10.1186/1475-2867-13-66⟩. ⟨inserm-00844782⟩
  • Marija Hiljadnikova Bajro, Elena Sukarova-Angelovska, Jose Adélaïde, Max Chaffanet, Aleksandar Dimovski. A new case with 10q23 interstitial deletion encompassing both PTEN and BMPR1A narrows the genetic region deleted in juvenile polyposis syndrome. Journal of Applied Genetics, Institute of Plant Genetics, 2013, 54 (1), pp.43-47. ⟨10.1007/s13353-012-0115-z⟩. ⟨hal-03634260⟩
  • S Cornen, J Adelaide, F Bertucci, P Finetti, A Guille, et al.. Mutations and deletions of ARID1A in breast tumors. Oncogene, Nature Publishing Group, 2012, 31 (38), pp.4255-4256. ⟨10.1038/onc.2011.598⟩. ⟨hal-03634289⟩
  • Max Chaffanet, L Addou-Klouche, J Adélaïde, S Cornen, I Bekhouche, et al.. Integrated Genomic Analysis of Breast Cancers. Balkan Journal of Medical Genetics, 2012, 15 (Supplement), pp.71-74. ⟨10.2478/v10034-012-0023-x⟩. ⟨hal-03634284⟩
  • Renaud Sabatier, Pascal Finetti, José Adelaide, Arnaud Guille, Jean-Paul Borg, et al.. Down-Regulation of ECRG4, a Candidate Tumor Suppressor Gene, in Human Breast Cancer. PLoS ONE, Public Library of Science, 2011, 6 (11), pp.e27656. ⟨10.1371/journal.pone.0027656⟩. ⟨hal-03623789⟩
  • Anne Letessier, Daniel Birnbaum, Michelle Debatisse, Max Chaffanet. La pauvreté en sites d’initiation de la réplication rend-elle fragile certaines régions du génome ?. médecine/sciences, EDP Sciences, 2011, 27 (8-9), pp.707-709. ⟨10.1051/medsci/2011278011⟩. ⟨hal-03634292⟩
  • Ismahane Bekhouche, Pascal Finetti, José Adelaïde, Anthony Ferrari, Carole Tarpin, et al.. High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes. PLoS ONE, Public Library of Science, 2011, 6 (2), pp.e16950. ⟨10.1371/journal.pone.0016950⟩. ⟨hal-03623798⟩
  • Christophe Ginestier, Fabrice Sircoulomb, Emmanuelle Charafe-Jauffret, Max Chaffanet, Daniel Birnbaum. ZNF703: a novel oncogene involved in breast cancer. médecine/sciences, EDP Sciences, 2011, 27 (4), pp.357-359. ⟨10.1051/medsci/2011274008⟩. ⟨hal-01431947⟩
  • M Brecqueville, N Cervera, V Gelsi-Boyer, A Murati, J Adélaïde, et al.. Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes. Blood Cancer Journal, Nature Publishing Group, 2011, 1 (5), pp.e18-e18. ⟨10.1038/bcj.2011.15⟩. ⟨hal-03634310⟩
  • M Brecqueville, N Cervera, J Adélaïde, J Rey, N Carbuccia, et al.. Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms. Blood Cancer Journal, Nature Publishing Group, 2011, 1 (8), pp.e33-e33. ⟨10.1038/bcj.2011.31⟩. ⟨hal-03634307⟩
  • David Birnbaum, José Adélaïde, Emilie Mamessier, Pascal Finetti, Arnaud Lagarde, et al.. Genome profiling of pancreatic adenocarcinoma. Genes, Chromosomes and Cancer, Wiley, 2011, 50 (6), pp.456-465. ⟨10.1002/gcc.20870⟩. ⟨hal-03583490⟩
  • Fabrice Sircoulomb, Nathalie Nicolas, Anthony Ferrari, Pascal Finetti, Ismahane Bekhouche, et al.. ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Molecular Medicine, Wiley Open Access, 2011, 3 (3), pp.153-166. ⟨10.1002/emmm.201100121⟩. ⟨hal-01431945⟩
  • G Fournier, O Cabaud, E Josselin, A Chaix, J Adélaïde, et al.. Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth. Oncogene, Nature Publishing Group, 2011, 30 (36), pp.3862-3874. ⟨10.1038/onc.2011.106⟩. ⟨hal-03634305⟩
  • Véronique Gelsi-Boyer, Virginie Trouplin, Julien Roquain, José Adelaïde, Nadine Carbuccia, et al.. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. British Journal of Haematology, Wiley, 2010, 151 (4), pp.365. ⟨10.1111/j.1365-2141.2010.08381.x⟩. ⟨hal-00580698⟩
  • J Adélaïde, V Gelsi-Boyer, J Rocquain, N Carbuccia, D Birnbaum, et al.. Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies. Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2010, 24 (8), pp.1539-1541. ⟨10.1038/leu.2010.135⟩. ⟨hal-03634330⟩
  • Anthony Gonçalves, Pascal Finetti, Renaud Sabatier, Marine Gilabert, José Adelaïde, et al.. -- mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Research and Treatment, Springer Verlag, 2010, 127 (1), pp.273-281. ⟨10.1007/s10549-010-1199-y⟩. ⟨hal-00594471⟩
  • Stéphane Raynaud, Nadine Carbuccia, Carole Colin, José Adélaïde, Marie-Joelle Mozziconacci, et al.. Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers. Oncology Letters, Spandidos Publications, 2010, 1 (5), pp.883-884. ⟨10.3892/ol_00000156⟩. ⟨hal-03634318⟩
  • N Carbuccia, V Trouplin, V Gelsi-Boyer, A Murati, J Rocquain, et al.. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2010, 24 (2), pp.469-473. ⟨10.1038/leu.2009.218⟩. ⟨hal-03634338⟩
  • Lynda Addou-Klouche, José Adélaïde, Pascal Finetti, Nathalie Cervera, Anthony Ferrari, et al.. Loss, mutation and deregulation of L3MBTL4 in breast cancers. Molecular Cancer, BioMed Central, 2010, 9 (1), pp.213. ⟨10.1186/1476-4598-9-213⟩. ⟨hal-03623805⟩
  • Julien Rocquain, Véronique Gelsi-Boyer, José Adélaïde, Anne Murati, Nadine Carbuccia, et al.. Alteration of cohesin genes in myeloid diseases. American Journal of Hematology, Wiley, 2010, 85 (9), pp.717-719. ⟨10.1002/ajh.21798⟩. ⟨hal-03634323⟩
  • Renaud Sabatier, José Adélaïde, Pascal Finetti, Anthony Ferrari, Laetitia Huiart, et al.. BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer. Genes, Chromosomes and Cancer, Wiley, 2010, 49 (12), pp.1143-1151. ⟨10.1002/gcc.20822⟩. ⟨hal-03623799⟩
  • Fabrice Sircoulomb, Ismahane Bekhouche, Pascal Finetti, José Adélaïde, Azza Ben Hamida, et al.. Genome profiling of ERBB2-amplified breast cancers. BMC Cancer, BioMed Central, 2010, 10 (1), pp.539. ⟨10.1186/1471-2407-10-539⟩. ⟨hal-03623802⟩
  • Véronique Gelsi-Boyer, Virginie Trouplin, José Adélaïde, Julien Bonansea, Nathalie Cervera, et al.. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. British Journal of Haematology, Wiley, 2009, 145 (6), pp.788-800. ⟨10.1111/j.1365-2141.2009.07697.x⟩. ⟨hal-03634359⟩
  • François Bertucci, Pascal Finetti, Nathalie Cervera, Emmanuelle Charafe-Jauffret, Max Buttarelli, et al.. How different are luminal A and basal breast cancers?. International Journal of Cancer, Wiley, 2009, 124 (6), pp.1338-1348. ⟨10.1002/ijc.24055⟩. ⟨hal-03623816⟩
  • F Bernard, V Gelsi-Boyer, A Murati, S Giraudier, V Trouplin, et al.. Alterations of NFIA in chronic malignant myeloid diseases. Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2009, 23 (3), pp.583-585. ⟨10.1038/leu.2008.228⟩. ⟨hal-03634341⟩
  • A Murati, C Gervais, N Carbuccia, P Finetti, N Cervera, et al.. Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases. Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2009, 23 (1), pp.85-94. ⟨10.1038/leu.2008.257⟩. ⟨hal-03634349⟩
  • N Carbuccia, A Murati, V Trouplin, M Brecqueville, J Adélaïde, et al.. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2009, 23 (11), pp.2183-2186. ⟨10.1038/leu.2009.141⟩. ⟨hal-03634354⟩
  • Pascal Finetti, Nathalie Cervera, Emmanuelle Charafe-Jauffret, Christian Chabannon, Colette Charpin, et al.. Sixteen–Kinase Gene Expression Identifies Luminal Breast Cancers with Poor Prognosis. Cancer Research, American Association for Cancer Research, 2008, 68 (3), pp.767-776. ⟨10.1158/0008-5472.can-07-5516⟩. ⟨hal-03623826⟩
  • Véronique Gelsi-Boyer, Virginie Trouplin, José Adélaïde, Nicola Aceto, Virginie Remy, et al.. Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1genes. BMC Cancer, BioMed Central, 2008, 8 (1), pp.299. ⟨10.1186/1471-2407-8-299⟩. ⟨hal-03634388⟩
  • Marie-Joëlle Mozziconacci, Nadine Carbuccia, Thomas Prebet, Aude Charbonnier, Anne Murati, et al.. Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110–FGFR1 fusion: Report of a new case and review of the literature. Leukemia Research, Elsevier, 2008, 32 (8), pp.1304-1308. ⟨10.1016/j.leukres.2007.11.012⟩. ⟨hal-03634385⟩
  • S Esteyries, C Perot, J Adelaide, M Imbert, A Lagarde, et al.. NCOA3, a new fusion partner for MOZ/MYST3 in M5 acute myeloid leukemia. Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2008, 22 (3), pp.663-665. ⟨10.1038/sj.leu.2404930⟩. ⟨hal-03634391⟩
  • José Adélaïde, Pascal Finetti, Emmanuelle Charafe-Jauffret, Julien Wicinski, Jocelyne Jacquemier, et al.. Absence of ESR1 amplification in a series of breast cancers. International Journal of Cancer, Wiley, 2008, 123 (12), pp.2970-2972. ⟨10.1002/ijc.23786⟩. ⟨hal-03623819⟩
  • J. Adelaide, P. Finetti, I. Bekhouche, L. Repellini, J. Geneix, et al.. Integrated Profiling of Basal and Luminal Breast Cancers. Cancer Research, American Association for Cancer Research, 2007, 67 (24), pp.11565-11575. ⟨10.1158/0008-5472.can-07-2536⟩. ⟨hal-03623830⟩
  • A. Murati, J. Adelaide, B. Quilichini, V. Remy, D. Sainty, et al.. New types of MYST3-CBP and CBP-MYST3 fusion transcripts in t(8;16)(p11;p13) acute myeloid leukemias. Haematologica, Ferrata Storti Foundation, 2007, 92 (2), pp.262-263. ⟨10.3324/haematol.10744⟩. ⟨hal-03634402⟩
  • Emmanuelle Charafe-Jauffret, Max Chaffanet, François Bertucci, Christophe Ginestier, Jocelyne Jacquemier, et al.. Towards an integrated cellular and molecular: definition of breast cancers. médecine/sciences, EDP Sciences, 2007, 23 (6-7), pp.626-632. ⟨10.1051/medsci/20072367626⟩. ⟨hal-01431964⟩
  • J. Jacquemier, D. Birnbaum, M. López, M. Chaffanet, A. Letessier, et al.. Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. Oncogene, Nature Publishing Group, 2007, 26 (2), pp.298-307. ⟨10.1038/sj.onc.1209772⟩. ⟨hal-01431963⟩
  • Anne Etienne, Nadine Carbuccia, José Adélaïde, Ismahane Bekhouche, Virginie Rémy, et al.. Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genes. Cancer Genetics and Cytogenetics, Elsevier, 2007, 176 (1), pp.80-88. ⟨10.1016/j.cancergencyto.2007.03.009⟩. ⟨hal-03634405⟩
  • Anne Etienne, Véronique Gelsi-Boyer, Nadine Carbuccia, José Adélaïde, Gianluca Barba, et al.. Combined translocation with ZNF198-FGFR1 gene fusion and deletion of potential tumor suppressors in a myeloproliferative disorder. Cancer Genetics and Cytogenetics, Elsevier, 2007, 173 (2), pp.154-158. ⟨10.1016/j.cancergencyto.2006.10.004⟩. ⟨hal-03634395⟩
  • V Gelsi-Boyer, N Cervera, F Bertucci, V Trouplin, V Remy, et al.. Gene expression profiling separates chronic myelomonocytic leukemia in two molecular subtypes. Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2007, 21 (11), pp.2359-2362. ⟨10.1038/sj.leu.2404805⟩. ⟨hal-03634397⟩
  • J Adélaïde, C Pérot, V Gelsi-Boyer, C Pautas, A Murati, et al.. A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma. Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2006, 20 (3), pp.536-537. ⟨10.1038/sj.leu.2404104⟩. ⟨hal-03634408⟩
  • Anne Letessier, Fabrice Sircoulomb, Christophe Ginestier, Nathalie Cervera, Florence Monville, et al.. Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers.. BMC Cancer, BioMed Central, 2006, 6, pp.245. ⟨10.1186/1471-2407-6-245⟩. ⟨inserm-00122145⟩
  • Christophe Ginestier, Nathalie Cervera, Pascal Finetti, Sverine Esteyries, Benjamin Esterni, et al.. Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clinical Cancer Research, American Association for Cancer Research, 2006, 12 (15), pp.4533-4544. ⟨10.1158/1078-0432.CCR-05-2339⟩. ⟨hal-01431971⟩
  • A Murati, J Adélaïde, V Gelsi-Boyer, A Etienne, V Rémy, et al.. t(5;12)(q23–31;p13) with ETV6-ACSL6 gene fusion in polycythemia vera. Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2006, 20 (6), pp.1175-1178. ⟨10.1038/sj.leu.2404194⟩. ⟨hal-03634410⟩
  • Anne Letessier, Christophe Ginestier, Emmanuelle Charafe-Jauffret, Nathalie Cervera, José Adélaïde, et al.. ETV6 gene rearrangements in invasive breast carcinoma. Genes, Chromosomes and Cancer, Wiley, 2005, 44 (1), pp.103-108. ⟨10.1002/gcc.20200⟩. ⟨hal-03634411⟩
  • A Letessier, M-J Mozziconacci, A Murati, J Juriens, J Adélaïde, et al.. Multicolour-banding fluorescence in situ hybridisation (mbanding-FISH) to identify recurrent chromosomal alterations in breast tumour cell lines. British Journal of Cancer, Cancer Research UK, 2005, 92 (2), pp.382-388. ⟨10.1038/sj.bjc.6602228⟩. ⟨hal-03634413⟩
  • A Murati, V Gelsi-Boyer, J Adélaïde, C Perot, P Talmant, et al.. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2005, 19 (9), pp.1692-1696. ⟨10.1038/sj.leu.2403879⟩. ⟨hal-03634415⟩
  • Véronique Gelsi-Boyer, Béatrice Orsetti, Nathalie Cervera, Pascal Finetti, Fabrice Sircoulomb, et al.. Comprehensive profiling of 8p11-12 amplification in breast cancer.. Molecular Cancer Research, American Association for Cancer Research, 2005, 3 (12), pp.655-67. ⟨10.1158/1541-7786.MCR-05-0128⟩. ⟨inserm-00158812⟩
  • Christophe Ginestier, Emmanuelle Charafe-Jauffret, Frédérique Penault-Llorca, Jeannine Geneix, José Adélaïde, et al.. Comparative multi-methodological measurement of ERBB2 status in breast cancer. Journal of Pathology, Wiley, 2004, 202 (3), pp.286-298. ⟨10.1002/path.1523⟩. ⟨hal-03634417⟩
  • Anne Murati, José Adélaïde, Marie-Joëlle Mozziconacci, Cornel Popovici, Nadine Carbuccia, et al.. Variant MYST4-CBP gene fusion in a t(10;16) acute myeloid leukaemia. British Journal of Haematology, Wiley, 2004, 125 (5), pp.601-604. ⟨10.1111/j.1365-2141.2004.04960.x⟩. ⟨hal-03634426⟩
  • M. Chaffanet, M. Baens, A. Aerssens, E. Schoenmakers, J.-J. Cassiman, et al.. Mapping of an ordered set of 14 cosmids to human chromosome 12p by two-color in situ hybridization. Cytogenetic and Genome Research, Karger, 2004, 69 (1-2), pp.27-32. ⟨10.1159/000133930⟩. ⟨hal-03634475⟩
  • Huai-En Huang, Suet-Feung Chin, Christophe Ginestier, Valérie-Jeanne Bardou, José Adélaïde, et al.. A Recurrent Chromosome Breakpoint in Breast Cancer at the NRG1 / Neuregulin 1 / Heregulin Gene. Cancer Research, American Association for Cancer Research, 2004, 64 (19), pp.6840-6844. ⟨10.1158/0008-5472.CAN-04-1762⟩. ⟨hal-03634416⟩
  • Géraldine Guasch, Cornel Popovici, Francine Mugneret, Max Chaffanet, Pierre Pontarotti, et al.. Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3). Blood, American Society of Hematology, 2003, 101 (1), pp.286-288. ⟨10.1182/blood-2002-02-0577⟩. ⟨hal-03634435⟩
  • José Adélaïde, Huai-En Huang, Anne Murati, Amber Alsop, Béatrice Orsetti, et al.. A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/ NRG1 gene. Genes, Chromosomes and Cancer, Wiley, 2003, 37 (4), pp.333-345. ⟨10.1002/gcc.10218⟩. ⟨hal-03634428⟩
  • Daniel Birnbaum, José Adélaïde, Cornel Popovici, Emmanuelle Charafe-Jauffret, Marie-Joelle Mozziconacci, et al.. Chromosome arm 8p and cancer: a fragile hypothesis. Lancet Oncology, Elsevier, 2003, 4 (10), pp.639-642. ⟨10.1016/S1470-2045(03)01225-7⟩. ⟨hal-03634434⟩
  • Christophe Ginestier, Valérie-Jeanne Bardou, Cornel Popovici, Emmanuelle Charafe-Jauffret, François Bertucci, et al.. Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer. International Journal of Cancer, Wiley, 2003, 107 (5), pp.854-862. ⟨10.1002/ijc.11462⟩. ⟨hal-03623844⟩
  • C. Popovici, C. Basset, F. Bertucci, A. Orsetti, J. Adelaide, et al.. Reciprocal translocations in breast tumor cell lines: Cloning of a t(3;20) that targets the FHIT gene. Genes, Chromosomes and Cancer, Wiley, 2002, 35 (3), pp.204--218. ⟨10.1002/gcc.10107⟩. ⟨hal-02197538⟩
  • Max Chaffanet, Laetitia Gressin, Claude Preudhomme, Val�rie Soenen-Cornu, Daniel Birnbaum, et al.. MOZ is fused top300 in an acute monocytic leukemia with t(8;22). Genes, Chromosomes and Cancer, Wiley, 2000, 28 (2), pp.138-144. ⟨10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2⟩. ⟨hal-03634438⟩
  • Max Chaffanet, Marie-Jo�lle Mozziconacci, Francisca Fernandez, Danielle Sainty, Marina Lafage-Pochitaloff, et al.. A case of inv(8)(p11q24) associated with acute myeloid leukemia involves theMOZ andCBP genes in a masked t(8;16). Genes, Chromosomes and Cancer, Wiley, 1999, 26 (2), pp.161-165. ⟨hal-03634445⟩
  • Xiao-Zhong Wang, Ethel Jolicoeur, Nathalie Conte, Max Chaffanet, yuhong Zhang, et al.. γ-heregulin is the product of a chromosomal translocation fusing the DOC4 and HGL/NRG1 genes in the MDA-MB-175 breast cancer cell line. Oncogene, Nature Publishing Group, 1999, 18 (41), pp.5718-5721. ⟨10.1038/sj.onc.1202950⟩. ⟨hal-03634449⟩
  • Cornel Popovici, José Adélaïde, Vincent Ollendorff, Max Chaffanet, Géraldine Guasch, et al.. Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13)(p12;q12). Proceedings of the National Academy of Sciences of the United States of America, National Academy of Sciences, 1998, 95 (10), pp.5712-5717. ⟨10.1073/pnas.95.10.5712⟩. ⟨hal-03634453⟩
  • Cornel Popovici, Jose Adelaide, Vincent Ollendorff, Max Chaffanet, Géraldine Guasch, et al.. Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). Proceedings of the National Academy of Sciences of the United States of America, National Academy of Sciences, 1998, 95 (10), pp.5712-5717. ⟨hal-02683853⟩
  • José Adélaïde, Max Chaffanet, Alexandra Imbert, Florence Allione, Jeanine Geneix, et al.. Chromosome region 8p11-p21: Refined mapping and molecular alterations in breast cancer. Genes, Chromosomes and Cancer, Wiley, 1998, 22 (3), pp.186-199. ⟨10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S⟩. ⟨hal-03634451⟩
  • Valérie Soenen, Max Chaffanet, Claude Preudhomme, Amel Dib, Jean-Luc Laï, et al.. Identification of a YAC spanning the translocation breakpoint t(8;22) associated with acute monocytic leukemia. Genes, Chromosomes and Cancer, Wiley, 1996, 15 (3), pp.191-194. ⟨10.1002/(SICI)1098-2264(199603)15:3<191::AID-GCC9>3.0.CO;2-Y⟩. ⟨hal-03634457⟩
  • A. Dib, J. Adelaide, M. Chaffanet, A. Imbert, D. Lepaslier, et al.. Characterization of the Region of the Short Arm of Chromosome-8 Amplified in Breast-Carcinoma. Oncogene, Nature Publishing Group, 1995, 10 (5), pp.995--1001. ⟨hal-02193511⟩
  • Jeroen Aerssens, Max Chaffanet, Mathijs Baens, Gert Mattijs, Herman van den Berghe, et al.. Regional Assignment of Seven Loci to 12p13.2-pter by PCR Analysis of Somatic Cell Hybrids Containing the der(12) or the der(X) Chromosome from a Mesothelioma Showing t(X;12)(q22;p13). Genomics, Elsevier, 1994, 20 (1), pp.119-121. ⟨10.1006/geno.1994.1136⟩. ⟨hal-03634485⟩
  • Mathijs Baens, Max Chaffanet, Jeroen Aerssens, Jean-Jacques Cassiman, Peter Marynen. Assignment of the Gene for the Human Proliferating Cell Nucleolar Protein P120 (NOL1) to Chromosome 12p13 by Fluorescence in Situ Hybridization and Polymerase Chain Reaction with Somatic Cell Hybrids. Genomics, Elsevier, 1994, 21 (1), pp.296-297. ⟨10.1006/geno.1994.1267⟩. ⟨hal-03634481⟩

Preprints, Working Papers, ...1 document

  • Camille Laberthonnière, Raphaël Chevalier, Camille Dion, Mégane Delourme, David Hirst, et al.. SMCHD1 variants may induce variegated expression in Facio Scapulo Humeral Dystophy and Bosma Arhinia and microphtalmia syndrome. 2022. ⟨hal-03634209⟩